Asset profile
Trelagliptin · Zafatek
Small molecule
Evidence outlook · results not reported
NCT03940183 · Diabetes Mellitus, Type 2
The lead study's design has limits that temper confidence (see the rationale below), and its results have not been reported. This tier describes the design, not an outcome.
NCT03940183: The trial randomized 254 participants to trelagliptin or placebo and used quadruple blinding. Its primary endpoint was the surrogate measure of change in HbA1c at week 24, but results were not posted, so whether the comparison favored trelagliptin is unknown.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
79 competitors in this universe: 19 direct rivals (same mechanism and indication), 0 same-class, 60 same-indication; 33 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Trelagliptin (Zafatek): this drug | Phase 3 | Small molecule | DPP-4 | ||
| Alogliptin (Nesina) | Approved | Small molecule | DPP-4 | ||
| Linagliptin (Tradjenta) | Approved | Small molecule | DPP-4 | ||
| Saxagliptin (Onglyza) | Approved | Small molecule | DPP-4 | ||
| Sitagliptin (Januvia) | Approved | Small molecule | DPP-4 | ||
| Anagliptin (Suiny) | Phase 3 | Small molecule | DPP-4 | ||
| DBPR108 | Phase 3 | Small molecule | DPP-4 | ||
| Evogliptin (Suganon) | Phase 3 | Small molecule | DPP-4 | ||
| Gemigliptin (Zemiglo) | Phase 3 | Small molecule | DPP-4 | ||
| Gosogliptin | Phase 3 | Small molecule | DPP-4 | ||
| Henagliflozin | Phase 3 | Small molecule | Sodium-glucose cotransporter 2 (SGLT2), DPP-4 | ||
| MP-513 | Phase 3 | Small molecule | DPP-4 | ||
| Omarigliptin (Marizev) | Phase 3 | Small molecule | DPP-4 | ||
| SP2086 | Phase 3 | Small molecule | DPP-4 | ||
| SYR-472 | Phase 3 | Small molecule | DPP-4 | ||
| Teneligliptin (Tenelia) | Phase 3 | Small molecule | DPP-4 |
…and 64 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Compare head-to-head
13 further head-to-head pairs are tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (1)
December 2026 (1)
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.